U.S. markets closed

Bio-Path Holdings, Inc. (BPTH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7200-0.1200 (-2.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.8400
Open4.8700
Bid4.4200 x 800
Ask4.7700 x 900
Day's Range4.7000 - 4.8900
52 Week Range2.9200 - 13.4100
Volume37,551
Avg. Volume77,482
Market Cap17.426M
Beta (5Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)-3.3000
Earnings DateAug 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020

    HOUSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, August 14, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020 and to provide a business overview. To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 3237808. A live audio webcast of the call will also be available on the Events section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event. About Bio-Path Holdings, Inc.Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.For more information, please visit the Company's website at http://www.biopathholdings.com.  Contact Information:InvestorsWill O’Connor Stern Investor Relations 212-362-1200 will@sternir.com Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369

  • Thomson Reuters StreetEvents

    Edited Transcript of BPTH.OQ earnings conference call or presentation 15-May-20 12:30pm GMT

    Q1 2020 Bio Path Holdings Inc Earnings Call

  • ACCESSWIRE

    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ:BPTH)

    DALLAS, TX / ACCESSWIRE / June 17, 2020 / Bio-Path Holdings, Inc. (NASDAQ:BPTH). The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/BPTH%20JUNE%202020.pdf ...